There's an alarming shortage of neurologists in the United States. That shortage makes it hard to be seen by a neurologist and, in some regions of the U.S., you may not even find an MS specialist without having to travel hundreds of miles. The good news is now there's an app for that!
Joining me to talk about how an app called BeCare is already changing the game when it comes to MS care is the Chief Medical Officer of BeCareLink, Dr. Charisse Litchman.
The FDA has designated Tolebrutinib as a Breakthrough Therapy for the treatment of adults with non-relapsing secondary progressive MS. We're sharing the details.
We'll tell you where you can participate in a phase 2 clinical trial that's designed to test the efficacy of Foralumab, an investigational disease-modifying therapy formulated as a nasal spray, among adults with non-relapsing secondary progressive MS.
We'll share the details of a report that provides some frustrating data about out-of-pocket costs for MS prescription medications.
Dr. Alicyn Magruder reviews the risks and benefits of using off-label medications to manage MS.
And we'll share the results of a study that focused on how socioeconomic status impacts disease severity among kids and teens living with MS.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: An app that can tell you if your MS is worsening :22
FDA awards Tolebrutinib Breakthrough Therapy designation 1:04
Phase 2 clinical trial for Foralumab adds 6 additional sites 3:13
Study compares out-of-pocket costs of MS DMTs with meds for other neurologic conditions 5:55
Dr. Alicyn Magruder discusses using off-label medications to manage MS 9:51
Study analyzes the impact of socioeconomic status on disease severity in pediatric-onset MS 15:27
Dr. Charisse Lichtman explains how the BeCare MS app is changing the game and providing an important bridge to better MS care 19:52
Share this episode 30:53
Have you downloaded the free RealTalk MS app? 31:13
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/381
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
RealTalk MS on YouTube
https://www.msif.org/webcast-clinical-trials
CLINICAL TRIAL: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
https://clinicaltrials.gov/study/NCT06292923
STUDY: Costs Are Still On the Rise for Commonly Prescribed Branded Neurologic Medications
https://neurology.org/doi/10.1212/WNL.0000000000210029
STUDY: Association of Social Determinants of Health with Brain MRI Outcomes in Individuals with Pediatric Onset Multiple Sclerosis
https://neurology.org/doi/10.1212/WNL.0000000000210140
Join the RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
Download the RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200
Download the RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 381
Guests: Dr. Alicyn Magruder, Dr. Charisse Litchman
